Ampio Pharma off 58% premarket on failed trial results

|About: Ampio Pharmaceuticals,... (AMPE)|By:, SA News Editor

Micro cap Ampio Pharmaceuticals (NYSEMKT:AMPE) craters 58% premarket on robust volume in response to its announcement that the Phase 3 clinical trial evaluating AP008 for the reduction in pain associated with osteoarthritis of the knee failed to reach its primary endpoint compared to placebo due to a larger-than-expected range of results in the placebo arm. The company is analyzing the data and will host a conference call in the near future to discuss the results.

Subscribe for full text news in your inbox